Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases

Published:2018-06-14 Issue:8 Volume:20 Page:
ISSN:1523-3782
Container-title:Current Cardiology Reports
language:en
Short-container-title:Curr Cardiol Rep

Author:

Emmi Giacomo,Urban Maria Letizia,Imazio Massimo,Gattorno Marco,Maestroni Silvia,Lopalco Giuseppe,Cantarini Luca,Prisco Domenico,Brucato Antonio

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/article/10.1007/s11886-018-1007-6/fulltext.html

Reference68 articles.

1. • Szekely Y, Arbel Y. A review of interleukin-1 in heart disease: where do we stand today? Cardiol Ther. 2018; https://doi.org/10.1007/s40119-018-0104-3 . Relevant review focused on the role of IL-1 in heart diseases and potential therapeutic effects of anti-IL-1 treatments.

2. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39(6):1003–18. https://doi.org/10.1016/j.immuni.2013.11.010 .

3. • Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatol Oxf Engl. 2015;54(12):2134–44. https://doi.org/10.1093/rheumatology/kev269 . Clinical review highlighting the role of interfering with IL-1 in cardiovascular diseases and type 2 diabetes, conditions that are frequently encountered as co-morbidities in patients with rheumatic diseases.

4. •• Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. JAMA. 2016;316(18):1906–12. https://doi.org/10.1001/jama.2016.15826 . First controlled, randomized trial to determine the efficacy of anakinra for colchicine-resistant and corticosteroid-dependent recurrent pericarditis.

5. •• Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31. https://doi.org/10.1056/NEJMoa1707914 . First controlled randomized double-blind trial to evaluate the efficacy of canakinumab for patients with previous myocardial infarction and a high-sensitivity C-reactive protein.

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interleukin-1 Blockers: A Paradigm Shift in the Treatment of Recurrent Pericarditis;Life;2024-02-26

2. Effectiveness and safety of IL1 inhibition with anakinra in chronic refractory idiopathic myocarditis;Internal and Emergency Medicine;2023-12-29

3. Preclinical Safety Evaluation of Engineered Lactococcus lactis NZ3900 Biotherapeutics Using a 13-Week Repeated Dose Oral Toxicity Study in Rabbits;Food Biotechnology;2023-07-03

4. Can Asthma Cause Pericardial Effusion? Insights Into an Intriguing Association;Texas Heart Institute Journal;2023-03-01

5. Efficacité de l’anakinra dans la polysérite réfractaire : étude multicentrique italienne;Revue du Rhumatisme;2022-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3